News & Analysis on Clinical Trial Services & Contract Research And Development
A bill unveiled by US senators yesterday would clear the way for the Food and Drug Administration (FDA) to approve low cost, generic versions of biotech medicines. There is currently no statutory pathway allowing such generic copies to enter the market.
A Japanese firm announced this week that it has developed a biodegradable polymer based drug delivery system that could significantly improve the efficacy of chemotherapy drugs and reduce drug development costs.
Australian contract manufacturing organisation (CMO) Eastland Medical Systems has bagged a manufacturing and distribution contract with UK's Proto-Pharma for its anti-malaria treatment.
Actavis has waded further into India and picked up new contract manufacturing capabilities along the way with the purchase of a division of Sanmar Specialty Chemicals (SSCL).
Invitrogen has decided to sell BioReliance, the 'beleaguered' pharmaceutical services arm of its business, for less than half the price they paid for it just three years ago.
Materia's metathesis platform continues to excite the pharmaceutical industry as they follow their recent license to Merck with a license to Aileron Therapeutics.
GlaxoSmithKline (GSK) has decided to consolidate all its human resources business process outsourcing (BPO) services under the one umbrella in a contract valued at $171m (€131m).